 Patients responding criteria for selection and not objecting to participate in this trial will address the quality of life questionnaires at baseline and during their standard follow-up 1, 6, 12 and 24 months after the end of radiotherapy. The data of toxicity and disease-free survival will be collected from data on medical record of the patient. 